This test is most useful if any of these apply to you.
Persistent itching or an eczema-like rash in later life can sometimes be the first sign of bullous pemphigoid. In this disease, your immune system attacks proteins that attach the outer skin to the tissue underneath. This blood test measures one of the antibodies involved and can help investigate symptoms before blisters appear.
The test is established as part of a diagnostic workup and for following disease activity after diagnosis. Its meaning depends on your symptoms, examination, and other findings. A positive result alone doesn't establish pemphigoid, and a negative result can miss it.
BP180 is a protein that helps attach cells at the base of your outer skin layer to the supporting tissue beneath them. Scientists also call it type XVII collagen. Part of the protein lies inside the cell, and part extends outside it.
Many people with bullous pemphigoid make antibodies against a section of BP180 called NC16A, which lies just outside the cell. Antibody binding can trigger inflammation and damage the structures that hold the skin layers together. Eosinophils are one type of white blood cell involved in this inflammation. The resulting separation can fill with fluid and form a blister.
This test measures IgG antibodies against BP180's NC16A region in serum using ELISA. Serum is the liquid left after blood clots. IgG is a major class of antibody in blood.
ELISA measures how much antibody binds to the NC16A material used in the assay. It reports a numerical level in assay-specific units. The number can be followed over time, but values from different manufacturers or methods aren't interchangeable, even when the unit labels look alike.
Bullous pemphigoid is the most common autoimmune blistering disease of the skin, though it remains uncommon. It mainly affects older adults. Some people have months of itching, raised red patches, or an eczema-like rash before developing blisters; others have a non-blistering form throughout their illness.
The disease can be serious. In one Austrian cohort of 100 people, a quarter died within a year of diagnosis. A Swedish nationwide study of 5,738 people found about twice the death rate of matched people without pemphigoid. These are findings from particular populations, not estimates of what will happen to you. Frailty, other illnesses, infections, and complications of treatment all contribute to the risk.
Dementia, stroke, and Parkinson's disease occur more often in people with pemphigoid than in comparison populations. BP180 is also expressed in parts of the nervous system, but the reason for these associations isn't fully established. A BP180 antibody result isn't a validated test for diagnosing or predicting a neurological disease.
Some cases are associated with medication exposure. DPP-4 inhibitors are diabetes medicines also known as gliptins, and they have one of the strongest documented drug associations with bullous pemphigoid. Immune checkpoint inhibitors used to treat cancer can also trigger the disease.
One study found a particularly strong association with cutaneous squamous cell carcinoma among people receiving checkpoint inhibitors. That study enrolled people who had already developed a skin-related immune side effect, so its risk estimate shouldn't be applied to everyone receiving immunotherapy.
Cases have also been reported after COVID-19 vaccination. An Italian series described 21 such cases, but a case series based on timing cannot establish that vaccination caused them. Of the 17 people tested for BP180 antibodies, 11 had positive results.
BP180 antibodies sometimes occur without bullous pemphigoid. The frequency varies with the people studied, the sample, and the method. These findings explain why symptoms and skin findings matter when interpreting a positive result.
| Who Was Studied | How Antibodies Were Assessed | What They Found |
|---|---|---|
| More than 7,000 healthy blood donors | Plasma screening with BIOCHIP immunofluorescence, followed by ELISA assessment of reactive samples | A small fraction, well under 1 in 100, reacted to BP180 NC16A in the screening assay; fewer met the ELISA's definition of positivity. This isn't the positive rate for the serum ELISA described here. |
| Dermatology patients with other skin conditions | Serum BP180 antibody testing | A meaningful minority tested positive, showing that other skin disorders can accompany a positive result. |
| 100 people with stroke and 100 healthy comparison participants | Serum BP180 NC16A ELISA | Antibodies were detected in 14% of the stroke group and 5% of the comparison group. The association doesn't establish that stroke caused the antibodies. |
Studies have also detected BP180 antibodies in people with Alzheimer's disease and in some people with other inflammatory skin conditions who have no pemphigoid symptoms. These results are often lower than those in active pemphigoid, but the distributions overlap. The antibody level alone cannot reliably separate these groups.
Antibodies can recognize different parts of BP180 and differ in their ability to damage skin. A blood result doesn't establish that those antibodies are producing the characteristic injury in your skin. Skin biopsy findings help connect the antibody result to the disease.
Stored blood samples show that BP180 or BP230 antibodies can sometimes appear years before pemphigoid develops. These observations haven't established a reliable way to predict who will develop disease. Published estimates of how many antibody-positive healthy people go on to develop pemphigoid are projections, not observed progression rates.
Testing people without symptoms hasn't been shown to improve health outcomes. There is also no established preventive treatment based solely on an isolated positive BP180 result.
An older meta-analysis found that BP180 ELISA detected about 87 of every 100 pemphigoid cases and gave negative results in about 98 of every 100 people without the disease. Performance was less favorable in some clinical settings. In a Dutch study of 1,125 people being evaluated for suspected pemphigoid, the test detected about 70% of confirmed cases.
In a US clinic series, BP180 ELISA alone detected 54% of cases, meaning it missed nearly half. Adding BP230 testing increased detection to about two thirds. The people included, treatment exposure, assay, and diagnostic criteria all affect these figures.
One reason for a negative result is that the assay checks only the NC16A region. In a study of 51 people with pemphigoid, four had antibodies directed against other parts of BP180 and tested negative on the standard NC16A ELISA. People with non-blistering disease can also have lower antibody levels.
Mucous membrane pemphigoid is a related group of diseases that can affect the mouth, eyes, and other moist surfaces. Antibodies may recognize other parts of BP180 or different proteins, so this NC16A test is less sensitive for that diagnosis.
In the Dutch study, adding BP180 ELISA to skin biopsy immunofluorescence and a blood antibody test using salt-split skin didn't improve initial diagnostic accuracy. This supports using the tests together according to the clinical question, with BP180 ELISA particularly useful for following established disease.
Once pemphigoid is diagnosed, serum BP180 IgG often follows disease activity. In a prospective study of 143 people, higher levels were associated with more active disease. BP230 IgG and BP180 IgE didn't show the same association in that cohort. IgE is a different antibody class, and findings about it don't directly describe this IgG result.
The relationship isn't exact. Antibody levels can remain raised after the skin improves, and some studies have found a weaker relationship between the number and disease severity. A change in the result needs to be read alongside itching, new blisters, healing, and examination findings.
The starting level has shown inconsistent value for predicting relapse. A study of 47 people found that higher baseline levels were associated with later relapse, but many people with high levels didn't relapse. A separate prospective study of 120 people found that levels measured later in treatment were more informative about relapse than the starting level alone.
In a Chinese cohort of 1,018 people, lower starting antibody levels were associated with a higher rate of reaching complete remission off treatment during follow-up. That finding doesn't mean that lowering the antibody by a particular amount guarantees remission.
Several studies have associated higher BP180 antibody levels at diagnosis with higher mortality. In the prospective study of 143 people, higher levels were also associated with poorer ability to manage daily activities. Austrian and Italian cohorts found associations with mortality after accounting for several other risk factors.
A meta-analysis combined three studies of BP180 antibody positivity and found an association with higher mortality. Those studies used ELISA or a different protein-binding method called immunoblotting. Their pooled result doesn't provide a personal survival estimate from your NC16A ELISA level.
The studies used different definitions of higher antibody levels and included people with different ages, illnesses, and treatments. No trial has shown that adjusting treatment to reach a particular antibody number improves survival. Your skin disease, function, other conditions, and treatment risks remain part of the assessment.
Repeated results can help show how your antibody response changes during established pemphigoid, especially if the result was clearly positive at diagnosis. A sustained rise can support concern about renewed activity, while a fall can support improvement. Neither substitutes for what is happening on your skin.
A trend is most interpretable when the same assay is used. There is no universal antibody target that proves the disease is cured, and a rising result doesn't reliably tell you exactly when a relapse will occur.
Evidence-backed interventions that affect your Bullous Pemphigoid BP180 Antibody level
Bullous Pemphigoid BP180 Antibody is best interpreted alongside these tests.